Advertisement

Topics

Incyte Eyes Big Phase III IDO Expansion, NewLink Plans First Pivotal Trial

14:58 EDT 4 May 2017 | SCRIP

NewLink is hoping FDA will accept its plans to run one Phase III registrational study of its IDO pathway inhibitor...

      

Related Stories

 

Original Article: Incyte Eyes Big Phase III IDO Expansion, NewLink Plans First Pivotal Trial

NEXT ARTICLE

More From BioPortfolio on "Incyte Eyes Big Phase III IDO Expansion, NewLink Plans First Pivotal Trial"

Quick Search
Advertisement
 

Relevant Topic

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...